The aim – to determine factors that may influence on the occurrence of early postoperative complications (EPC) of surgical myocardial revascularization in patients with stable coronary heart disease and to study the effect of perioperative drug therapy. Material and methods. In a single-center study, data from a prospective study of 155 patients with stable coronary heart disease consecutively selected for isolated coronary artery bypass graft surgery (CABG) were analyzed. In total, 84 EPC were registered in 66 patients during the hospital period; 89 patients had no complications. Groups of patients with and without complications were compared according to demographic parameters, risk factors, concomitant diseases, perioperative therapy, features of the CABG operation.Results. Most of the early complications (56 %) were the cases of postoperative atrial fibrillation/flutter. In unifactor analysis, the features of patients with complications in the early postoperative period were the presence of severe diabetes (Р=0.025), obesity of I and II degrees (Р=0.070), left ventricle hypertrophy (median (quartiles) 47.9 (41.8–63.1) g/m2.7 vs 43.6 (36.5–55.2) g/m2.7; Р=0.008), the left atrium increase size (median (quartiles) 4.3 (4.2–4.6) cm vs 4.2 (4.0–4.5) cm; Р=0.068); elevated preoperative level of IL-6 (median (quartiles) 4.1 (3.1–9.0) pg/ml vs 3.2 (2.0–5.1) pg/ml; Р=0.044); the absence of statin therapy in perioperative period (Р<0.001) and a long duration of aortic clamping (median (quartiles) 20 (15–25) min vs 17 (13–23) min; Р=0.049). According to the multivariate analysis, the risk of EPC after CABG was 6.25 times higher among patients who did not take statins in the perioperative period, compared to patients who received high-intensity statins for ≥ 7 days. In patients with severe diabetes, the risk of EPC was 1.96 times higher than in patients with mild diabetes.Conclusions. The presence of severe diabetes and the absence of statin therapy in the perioperative period proved to be independent predictors of the occurrence of EPC. High-intensity statins therapy for ≥ 7 days prior to surgery allowed to reduce the risk of EPC, in particular, post-operative atrial fibrillation/flutter.
The aim: To determine the role of adherence to the guidelines on basic pharmacotherapy in prevention of late major adverse clinical events (MAEs) in patients with stable CAD for three years following isolated CABG.
Materials and methods: A prospective single-centre study included 251 consecutive patients with stable CAD (mean age (61±9) years, 218 (86.9%) males), after isolated CABG. In three years MAЕs occurred in 55 (21.9%) patients. The data on pharmacotherapy at follow-up were obtained in 250 patients: 196 (78.4%) patients without MAEs (at scheduled visit) and 54 (21.6%) patients with MAEs (based on in-hospital or archive data).
Results: Basic CAD pharmacotherapy after CABG was comparable in MAEs vs. no-MAEs groups, with the vast majority of patients receiving guideline-recommended therapy with angiotensin-converting enzyme inhibitors (ACEII) or angiotensin-II receptors blockers (ARBs), statins and antiplatelet drugs. At three years follow-up, MAEs group, as opposed to no-MAEs group, was characterized by the lower usage of ACEII/ARBs (68.5% vs. 87.2%, respectively; p=0,001) and statins (59.3% vs. 86.7%, respectively; p<0,001), as well as basic triple therapy (ACEII or ARBs/statins/antiplatelet drugs: 35.2% vs. 70.4%, respectively [p<0,001]).
Conclusions: At three – year follow-up MAEs in patients with stable CAD after CABG were associated with more frequent discontinuation of previously prescribed basic pharmacotherapy, namely ACEII/ARBs and statins, as well as triple therapy (ACEII/ARBs, statins and antiplatelet drugs).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.